MYRIAD GENETICS INC - 8-K Filing

Myriad Genetics reports Q2 2026 revenue decline to $190.7M, revises full-year guidance due to volume and pricing pressures (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $MYGN

Read the full article at SEC EDGAR

More Regulatory news